Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Shamsah Kazani"'
Publikováno v:
Trials, Vol 21, Iss 1, Pp 1-4 (2020)
Abstract Objectives Primary Objective • To evaluate the effect of ravulizumab, a long-acting complement (C5) inhibitor plus best supportive care (BSC) compared with BSC alone on the survival of patients with COVID-19. Secondary Objectives • Numbe
Externí odkaz:
https://doaj.org/article/66cf5524846748598d55b2efea28cb82
Autor:
Djillali Annane, Sean J Pittock, Hrishikesh S Kulkarni, Brian W Pickering, Matt R Khoshnevis, Jason L Siegel, Charles A Powell, Pedro Castro, Tomoko Fujii, Derek Dunn, Keisha Smith, Sanjay Mitter, Shamsah Kazani, Austin Kulasekararaj
Publikováno v:
The Lancet Respiratory Medicine.
Autor:
Shamsah Kazani, Ian D. Pavord, Veit J. Erpenbeck, Yuan Ye, Jian Luo, Eric A. Shikatani, Rowie Borst, Wentao Chen, Paul Klenerman, Wei Liu, David Andrew Sandham, Ryan D. Hoyle, Luzheng Xue
Publikováno v:
The Journal of Immunology. 206:2714-2724
Human type 2 cytotoxic T (Tc2) cells are enriched in severe eosinophilic asthma and can contribute to airway eosinophilia. PGD2 and its receptor PGD2 receptor 2 (DP2) play important roles in Tc2 cell activation, including migration, cytokine producti
Autor:
Jose Alcantara, Kenneth Kulmatycki, David J. Rowlands, Nicholas J. Simmonds, Lidia Mostovy, Surendra Machineni, Ivan Bottoli, Phaninatha Sarma Ayalavajjala, Robert M. Strieter, Henry Danahay, Shamsah Kazani, Raju Vegesna, Jerry A. Nick, Ieuan Jones, Mohammed Salman, Steven M. Rowe, Ian Nicholls, Martin Gosling, Julie Milojevic, Jeroen Verheijen
Publikováno v:
Journal of Cystic Fibrosis. 20:250-256
Background This is the first-in-human study of icenticaftor, an oral potentiator of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) channel. Restoration of CFTR activity has shown significant clinical benefits, but more studies ar
Autor:
Jens M. Hohlfeld, Christina Gress, Saskia Carstensen, Shamsah Kazani, David Andrew Sandham, Veit J. Erpenbeck, Meike Müller
Publikováno v:
Respiratory Research
Respiratory Research, Vol 22, Iss 1, Pp 1-11 (2021)
Respiratory Research, Vol 22, Iss 1, Pp 1-11 (2021)
BackgroundProstaglandin D2(PGD2) signaling via prostaglandin D2receptor 2 (DP2) contributes to atopic and non-atopic asthma. Inhibiting DP2has shown therapeutic benefit in certain subsets of asthma patients, improving eosinophilic airway inflammation
Autor:
Wentao, Chen, Jian, Luo, Yuan, Ye, Ryan, Hoyle, Wei, Liu, Rowie, Borst, Shamsah, Kazani, Eric A, Shikatani, Veit J, Erpenbeck, Ian D, Pavord, Paul, Klenerman, David A, Sandham, Luzheng, Xue
Publikováno v:
The Journal of Immunology Author Choice
Key Points Multiple proinflammatory effects of Tc2 cells are inhibited by DP2 antagonism. Tissue-remodeling functions of Tc2 cells are attenuated by DP2 antagonism. Autocrine/paracrine PGD2 production in Tc2 cells is reduced by DP2 antagonism.
H
H
Publikováno v:
D69. ASTHMA SUBPHENOTYPES, TARGETS AND THERAPEUTICS.
Autor:
Serpil C. Erzurum, Shamsah Kazani, Kartik Shenoy, Allison Crosby-Thompson, Mario Castro, Katherine N. Cahill, Joshua A. Boyce, Juying Lai, Michael E. Wechsler, Tanya M. Laidlaw, Jennifer Trevor, Elliot Israel, Emily DiMango, Vernon M. Chinchilli, Jing Cui, Denise Garofalo, Nizar N. Jarjour, Howard R. Katz
Publikováno v:
New England Journal of Medicine. 376:1911-1920
Mast cells are present in the airways of patients who have severe asthma despite glucocorticoid treatment; these cells are associated with disease characteristics including poor quality of life and inadequate asthma control. Stem cell factor and its
Publikováno v:
Allergy and immunology.
Introduction: Fevipiprant is a selective prostaglandin D2 receptor 2 (DP2) antagonist which reduces eosinophilic airway inflammation in patients with persistent asthma and raised sputum eosinophil counts. The DP2 receptor is activated by prostaglandi
Autor:
Shamsah Kazani, David Andrew Sandham, Petra Jaeger, Franziska Hasler, Claudine Maurer, Till Roehn
Publikováno v:
Allergy and immunology.
Background: Fevipiprant is a selective prostaglandin D2 receptor 2 (DP2) receptor antagonist which reduces eosinophilic airway inflammation in patients with persistent asthma and elevated sputum eosinophil counts. CD4+Th2 cells are a source of type 2